Cargando…
Adalimumab/golimumab/infliximab: SARS-CoV-2 pneumonia: 3 case reports
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880215/ http://dx.doi.org/10.1007/s40278-021-90751-6 |
Ejemplares similares
-
An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016) -
Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019) -
Adalimumab/vedolizumab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021) -
Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022) -
Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)